Diagnostic Stocks Poised for Growth Amid Post-Pandemic Shifts
TL;DR
Investors can focus on diagnostic companies that have adapted and are now on the upswing, like Exact Sciences (NASDAQ: EXAS).
Exact Sciences (NASDAQ: EXAS) has developed early cancer screening tests, including a colon cancer screening kit called Cologuard, helping to increase testing volumes.
Exact Sciences (NASDAQ: EXAS) is contributing to making the world a better place by reinventing themselves and developing early cancer screening tests, aiding in the early detection and treatment of cancer.
Ludwig Enterprises Inc. (OTCMKTS: LUDG) is a disruptive diagnostic testing company with revolutionary mRNA testing technology that could change the industry.
Found this article helpful?
Share it with your network and spread the knowledge!
Big diagnostic companies saw a surge during the pandemic due to mandated government testing. However, the shift to at-home kits and insurance coverage led to a collapse in COVID-19 testing revenues. Now, the sector's opportunity lies in companies that have reinvented themselves by developing early cancer screening tests.
Exact Sciences (NASDAQ: EXAS) stands out in this arena with its at-home colon cancer screening kit, cologuard. Testing volumes, which dropped during the pandemic, have rebounded, with the company reporting a record 1.0 million screenings in Q2 2024. The expansion into breast, prostate, and colon cancer screenings, along with a move into precision oncology through the acquisition of Thrive Early Detection Corp. for $2.15 billion, positions EXAS as a leader in the diagnostic sector.
Guardant Health Inc. (NASDAQ: GH) offers the first FDA-approved primary screening blood test for colorectal cancer, called Shield. Covered under Medicare, Shield has an 83% sensitivity and 90% specificity for advanced neoplasia. The company has $600 million in trailing revenues and a $4.0 billion market cap, making it a significant player in non-invasive cancer screening tests.
Illumina Inc. (NASDAQ: ILMN) provides genetic testing equipment crucial for large-scale analysis of genetic variations. The company recently spun off its diagnostics business, Grail Inc. (NASDAQ: GRAL), which focuses on early cancer screening through its Galleri test. Funded with a one-time cash payment of $923 million, Galleri tests for 50+ types of cancer using DNA sequencing technology from Illumina platforms, awaiting FDA approval.
Ludwig Enterprises Inc. (OTCMKTS: LUDG) is an emerging disruptor with mRNA testing technology aiming to revolutionize the diagnostic screening industry. The company's Lab Developed Test (LDT) for breast cancer, set to launch in October, boasts a 97% sensitivity rate and uses AI algorithms for a personalized inflammatory index. The test kits, priced at $249, will leverage direct-to-consumer viral marketing strategies.
As the diagnostic sector pivots towards early cancer detection and innovative testing technologies, these four companies represent a diversified investment opportunity, reflecting the industry's potential for significant growth and adaptation in the post-pandemic landscape.
Curated from News Direct
